FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses (EVO ICL™) for vision correction, ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the ...
DELRAY BEACH, Fla., Nov. 26, 2025 /PRNewswire/ -- The global Intraocular Lens Market, valued at US$4.38 billion in 2024, stood at US$4.62 billion in 2025 and is projected to advance at a resilient ...
†Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data. **Based on worldwide unit sales of AcrySof® IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024. “As ophthalmic practices ...
Data on Alcon’s products across cataract, refractive, diagnostics and ocular health will be featured in presentations during the meeting Prospective analyses and studies demonstrate sustained ...